Kirn David 13D and 13G filings for 4D Molecular Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 4:37 pm Purchase |
2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
Kirn David | 2,033,069 4.700% |
10,571 (+0.52%) |
Filing |
| 2023-02-08 4:15 pm Sale |
2022-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
Kirn David | 2,022,498 6.200% |
-11,877 (-0.58%) |
Filing |
| 2022-02-14 4:33 pm Purchase |
2021-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
Kirn David | 2,034,375 6.300% |
34,375 (+1.72%) |
Filing |
| 2021-02-12 9:33 pm Purchase |
2020-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
Kirn David | 2,000,000 7.500% |
2,000,000 (New Position) |
Filing |